top of page
Abstract Line Pattern

Biliary Tract Cancer

Biliary Tract Cancer

DESTINY-BTC01 — Phase 3 Clinical Trial

A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First-Line Locally Advanced or Metastatic HER2-Expressing Biliary Tract Cancer.


Principal Investigator (PI)

Clinical Trials.gov ID

Key Eligibility

Protocol #

SPONSOR

AstraZeneca
bottom of page